Table 3 Patient & disease characteristics of patients with PSM, stratified by biochemical recurrence at end of study period
Variable | BCR-free | BCR | All PSMs | p value |
|---|---|---|---|---|
N (%) | 125 (89.3) | 15 (10.7) | 140 | |
Patient age at time of surgery | ||||
Under 65 years | 60 (48.0) | 7 (46.7) | 67 (47.9) | 0.4 |
65 years and above | 65 (52.0) | 8 (53.3) | 73 (52.1) | |
Pre-op PSA | ||||
0.0-9.9 | 81 (64.8) | 4 (26.7) | 85 (60.7) | 0.003 |
10.0-19.9 | 38 (30.4) | 7 (46.7) | 45 (32.1) | |
20.0 and above | 6 (4.8) | 4 (26.7) | 10 (7.2) | |
Pathological Gleason score | ||||
Group 1 (GS 2-6) | 20 (16.0) | 0 | 20 (14.3) | 0.4 |
Group 2 (GS 3+4) | 59 (55.2) | 8 (53.3) | 77 (55.0) | |
Group 3 (GS 4+3) | 18 (14.4) | 5 (33.3) | 23 (16.4) | |
Group 4 (GS 8) | 13 (10.4) | 2 (13.3) | 15 (10.7) | |
Group 5 (GS 9-10) | 5 (4.0) | 0 | 5 (3.6) | |
Surgical approach | ||||
LRP | 75 (60.0) | 10 (66.7) | 85 (60.7) | 0.6 |
RARP | 50 (40.0) | 5 (33.3) | 55 (39.3) | |
Tumour volume of excised specimen | ||||
Median (IQR) | 3.7 (1.7-6.6) | 5.1 (2.5-10.2) | 3.8 (1.8-6.7) | <0.001 |
Pathological tumour stage | ||||
pT2 | 67 (53.6) | 5 (33.3) | 72 (51.4) | 0.4 |
pT3a | 44 (35.2) | 6 (40.0) | 50 (35.7) | |
pT3b | 14 (11.2) | 4 (26.7) | 18 (12.9) | |
Lymph node involvement | 7 (13.5) | 0 (0.0) | 0 (11.5) | 0.4 |
Margin location | ||||
Apex | 33 (26.4) | 4 (26.7) | 37 (26.4) | 0.4 |
Base | 23 (18.4) | 1 (6.7) | 24 (17.1) | |
Multifocal | 19 (15.2) | 5 (33.3) | 24 (17.1) | |
Other | 50 (40.0) | 5 (33.3) | 55 (39.3) | |
Adjuvant therapy | ||||
Salvage radiotherapy | 12 of 41 (29.3) | 10 of 14 (64.1) | 22 of 55 (40.0) | |
Radiotherapy & hormones | 0 | 1 of 14 (7.2) | 1 of 55 (1.8) | |
Missing | 84 | 1 | 85 | |